PharmaSwiss picks up CEE rights to Eisai's Halaven
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals' PharmaSwiss division has gained rights to promote and distribute Eisai's Halaven (eribulin) in selected Central and Eastern European countries, expanding the cancer drug's reach to markets where the Japanese firm has only a limited presence.